SSG
FULC icon

Summit Securities Group’s Fulcrum Therapeutics FULC Stock Holding History

Summit Securities Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,975
Closed -$53.5K – 1232
2026
Q1 		$53.5K Buy
+6,975
New +$64.7K 0.01% 381
2025
Q4 		– Sell
-2,917
Closed -$26.8K – 1090
2025
Q3 		$26.8K Buy
+2,917
New +$21.1K 0.01% 715

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Summit Securities Group's FULC Position: Q2 2026 in Review

Summit Securities Group sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 6,975 shares — an estimated $53.5K sold.

Summit Securities Group first reported a position in FULC in Q3 2025 and held it in 2 quarters. The position peaked at $53.5K in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Summit Securities Group reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 6,975 Fulcrum Therapeutics shares in Q2 2026, an estimated $53.5K.
  • Summit Securities Group first reported a position in Fulcrum Therapeutics in Q3 2025 and held it in 2 quarters.
  • Summit Securities Group's Fulcrum Therapeutics position peaked at $53.5K in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.